Qiagen NV | QIA - Interest Expense On Debt


Qiagen NV reported $10.14M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Akebia Therapeutics 362.52M 357.69M Mar/2026
Alaunos Therapeutics USD 1.07M 215K Jun/2023
argenx SE USD 1000K 172K Mar/2026
Avita Medical AUD 1.25M 100K Jun/2025
Dianthus Therapeutics USD 4.44M 263K Sep/2024
Ionis Pharmaceuticals USD 17M 1000K Mar/2026
IQVIA Holdings USD 192M 1000K Mar/2026
Moderna USD 11.49B 36B Mar/2026
Organon & Co USD 111M 17M Mar/2026
Qiagen NV USD 10.14M 1.92M Dec/2025
Revvity USD 24.72M 1.2M Mar/2026
Tectonic Therapeutic USD 246.58M 246.56M Mar/2026
Viatris USD 120.1M 500K Mar/2026
Xeris Pharmaceuticals USD 6.88M 269K Mar/2026